Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM-101 in adults with primary sclerosing cholangitis
2018-004258-77Phase 2Terminated
- Sponsor
- Chemomab Therapeutics
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nebokitug in Primary Sclerosing Cholangitis (PSC), sponsored by Chemomab Therapeutics. Primary endpoint: Activity of CM-101 measured by decrease in alkaline phosphatase. Started Nov 2018; status: terminated.
02
Drugs
nebokitug
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2018-004258-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004258-77.